Alpha Tau Medical

25/09/2025

🚀 On Our Way to ASTRO 2025!

Next week our Alpha TAU team is heading to San Francisco for the 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO) 2025. This year’s theme, “Rediscovering Radiation Medicine and Exploring New Indications,” connects directly to what we do every day: pushing the boundaries of cancer treatment.

With Alpha DaRT® - our pioneering intra-tumoral radiotherapy - we’re delivering targeted alpha radiation directly into solid tumors, now available only in clinical trials.

This year, we’re especially proud to share how we’re expanding into new indications:
✅ Treating immunocompromised patients suffering from recurrent SCC.
✅ Advancing toward a new study in Glioblastoma Multiforme (GBM) after FDA IDE approval.
✅ Exploring solutions for pancreatic cancer, one of the toughest unmet needs in oncology.

We’re excited to meet global leaders in radiation oncology, share our progress, and continue redefining the future of radiation medicine.

📍 Come visit us at booth #2417 in San Francisco!

22/09/2025

18/09/2025

Today, Alpha TAU’s employees gathered to mark the Jewish New Year (Rosh HaShanah) with a toast and an extraordinary lecture.

We had the honor of hearing from Tal Shoham, who had been kidnapped from Kibbutz Be’eri by Hamas on October 7 along with seven members of his family, released after 505 harrowing days in captivity.

His story of survival of cruel and abusive captors in inhumane conditions in tunnels underground, through astounding strength of character and resolve, was inspiring and unforgettable.

We take this opportunity to wish our dear partners and friends worldwide a happy New Year, and we pray for the safe return of all those still held in captivity. May we all be blessed in the coming year with abounding peace and prosperity.

11/09/2025

Recently we announced that the first patient was successfully treated in our U.S. multi-center trial 💪.

Coming to American Society for Radiation Oncology (ASTRO) 2025 and want to find out what else is in store for us? Our meetings are fully booked, but good news - you can still catch us at our special evening:

🌅 Golden Sunset, Breakthrough Science, and BBQ by the Bay (September 29 | 17:15–21:30, location details to be provided following registration).

Come and discover how our technology aims to open new doors for radiation oncologists looking for new ways to treat cancers. And we will do so with some necessary cocktails and sizzling BBQ.

10/09/2025

And this time on Alpha TAU’s Employee Spotlight: Gili Matias, Information Systems Specialist, Employee of the Year award winner, and generally just a warm, open, and friendly person we’re lucky to have with us.

It’s been quite a year for Gili. after 2.5 years at Alpha TAU, his professional contributions have been formally recognized, and in just one month he’s getting married! 💍

On the job, Gili is responsible for Alpha TAU’s information systems - planning, developing, and adapting technological solutions that keep our work accurate and efficient. One standout project: adapting our systems to the company’s complex production processes. As he puts it: “I really enjoy the combination of technology and people. Technology helps us push our capabilities forward - and working with a smile makes everything easier.”

Gili's manager, Liron Sofer, couldn't resist and insisted on adding some more superlatives: "Gili is the employee that every manager wants on their team. He is creative, thinks outside the box, responsible, and creates a good and pleasant atmosphere. It is a privilege and a great pleasure to work with him!"

Outside of work, Gili enjoys quality time with friends and family, exploring new places (most recently southern Spain), sharing dinners and good wine, and cooking together with his fiancée.

02/09/2025

𝗔𝗹𝗽𝗵𝗮 𝗧𝗮𝘂 𝗦𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹𝗹𝘆 𝗧𝗿𝗲𝗮𝘁𝘀 𝗙𝗶𝗿𝘀𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻 𝗶𝘁𝘀 𝗨.𝗦. 𝗠𝘂𝗹𝘁𝗶-𝗖𝗲𝗻𝘁𝗲𝗿 𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹

➡️ First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program.

➡️ Study explores 𝗔𝗹𝗽𝗵𝗮 𝗗𝗮𝗥𝗧® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.

➡️ Up to 87% of newly diagnosed pancreatic cancer patients are considered inoperable at diagnosis and face a dismal prognosis, with limited benefit from existing therapies.

➡️ This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs.

👉 𝘙𝘦𝘢𝘥 𝘵𝘩𝘦 𝘧𝘶𝘭𝘭 𝘪𝘯𝘵𝘦𝘳𝘷𝘪𝘦𝘸 𝘪𝘯 𝘵𝘩𝘦 𝘧𝘪𝘳𝘴𝘵 𝘤𝘰𝘮𝘮𝘦𝘯𝘵.

01/09/2025

Honoring Our U.S. Team This Labor Day

At Alpha Tau Medical, our mission is built on collaboration that spans borders, and today we take special pride in recognizing the hard work and commitment of our U.S. team, whose contributions play a vital role in advancing our dream to bring hope to cancer patients and families worldwide.

is a reminder that progress comes from the passion and perseverance of people who believe in making a difference. We are grateful to our amazing team in the US and wish them and their loved ones a joyful, restful, and well-deserved holiday. Thank you for everything you do. Together, we are building something extraordinary.

28/08/2025

Cancer’s escape routes - and the mission to block them.

Cancer doesn’t just grow - it adapts. Cancer therapy can act like a roadblock, but tumors are skilled at finding detours.

That’s what we mean by “escape routes.” If chemotherapy blocks a cancer cell’s ability to copy its DNA, the tumor may switch to backup repair mechanisms. If one treatment disrupts its growth, the tumor can slow down and wait until the threat passes. In other words, cancer learns to evade the very mechanism designed to stop it.

This is why combination therapies are now one of the most intensively investigated strategies in oncology. By pairing different, complementary approaches, we may be able to close more of the detours. For example, chemotherapy can damage the cancer’s ability to multiply, while radiotherapeutics (radiotherapy medicine, such as alpha particle radiotherapy) may be able to deliver targeted strikes that not only kill cells but also stimulate the body’s natural immune system. Each therapy works together to make it harder for the tumor to escape the other.

The future of cancer care lies in smarter combinations - not one-size-fits-all, but carefully tailored strategies that slow tumors down, extend survival, and fit the biology of each cancer and the needs of each patient.

27/08/2025

Alpha Tau Medical announced that CFO Raphi Levy will presentation in the following investor conferences in September 2025.

𝗘𝘃𝗲𝗻𝘁: 𝗖𝗶𝘁𝗶 𝟮𝟬𝟮𝟱 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗕𝗮𝗰𝗸 𝘁𝗼 𝗦𝗰𝗵𝗼𝗼𝗹 𝗦𝘂𝗺𝗺𝗶𝘁
🟢 Format: 1x1 Meetings
🟢 Date: September 2-3
🟢 Location: Boston, MA

𝗘𝘃𝗲𝗻𝘁: 𝗛.𝗖. 𝗪𝗮𝗶𝗻𝘄𝗿𝗶𝗴𝗵𝘁 𝟮𝟳𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗚𝗹𝗼𝗯𝗮𝗹 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲
🔵 Format: Company Presentation and 1x1 Meetings
🔵 Date: September 9, 2025
🔵 Time: 3:00 - 3:30pm
🔵 Location: New York, NY

𝗘𝘃𝗲𝗻𝘁: 𝗢𝗽𝗽𝗲𝗻𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗧𝗵𝗶𝗿𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗦𝘂𝗺𝗺𝗶𝘁
🟣 Format: 1x1 Meetings
🟣 Date: September 11, 2025
🟣 Location: New York, NY

𝗘𝘃𝗲𝗻𝘁: 𝗥𝗧𝗛 & 𝗖𝗼 / 𝗥𝗲𝗱𝗯𝘂𝗿𝗻 𝗔𝘁𝗹𝗮𝗻𝘁𝗶𝗰 - 𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲
🟤 Format: 1x1 Meetings
🟤 Date: September 26, 2025
🟤 Location: New York, NY

𝗘𝘃𝗲𝗻𝘁: 𝗟𝘆𝘁𝗵𝗮𝗺 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝗙𝗮𝗹𝗹 𝟮𝟬𝟮𝟱 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲
🟡 Format: 1x1 Meetings
🟡 Date: September 30, 2025
🟡 Location: Virtual

To read the full announcement, please read:
https://www.alphatau.com/single-post/alpha-tau-to-participate-in-five-september-investor-conferences

20/08/2025

Another powerful contribution from Dr. Robert Den, Alpha Tau’s Chief Medical Officer, featured in Psychology Today

With over 12 million monthly readers, we’re glad to see Dr. Den’s important insights getting the wide coverage it deserves in his latest piece highlighting why “the future of cancer treatment may lie in combination therapy.”

In the article, Dr. Den notes a growing shift in oncology, from monotherapy to carefully designed and personalized combination therapies because “Tumors are adaptive and complex; they can find ways to bypass even the most sophisticated therapies. This is why combination regimens are increasingly vital: they not only improve outcomes but can also reduce drug resistance, slow tumor growth, and trigger cancer cell death.”

Against this backdrop, Dr. Den underscores the potential of Alpha DaRT® in combination approaches. One early study pairing Alpha DaRT with immunotherapy (pembrolizumab) in recurrent or metastatic head & neck cancer showed responses “notably higher than the typical response rates observed with pembrolizumab alone,” with no additional side effects.

This is the kind of forward-thinking research that reflects Alpha Tau’s vision: leveraging intratumoral alpha radiotherapy not in isolation, but as a synergistic partner to systemic therapies - with the potential to unlock new hope for patients worldwide.

📖 Read the full article in the comments below.

12/08/2025

Alpha Tau Medical Announces Second Quarter 2025
Financial Results and Provides Corporate Update.

➡️ FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -

➡️ Multiple U.S. clinical trials, including pancreatic cancer and GBM pilot studies, positioned for imminent patient treatment initiation during the remainder of 2025 -

➡️ Secured $36.9 million through a strategic equity offering at market price from Oramed, while concurrently entering into a strategic IR/PR alliance -

➡️ Cash, cash equivalents & deposits balance of $83.3 million provides runway for continued clinical advancement and commercial preparation -

To read the full announcement - link in the comments

31/07/2025

Hadar Elimelech’s story is one of talent, tenacity, and true growth. She joined Alpha TAU nearly five years ago, right in the midst of the COVID-19 pandemic - as a production technician in our late Tel Aviv lab. From day one, her mindset was clear: “I’ll master whatever I’m taught - and I’ll do it better than anyone expects.” That drive, paired with a deep sense of purpose, quickly set her apart. Today, Hadar leads as Deputy Head of Production & Production Planner. Her professional ascent is even more powerful in light of the personal loss she went through. Hadar has faced profound family loss - including the passing of both her sister and her father.

In her current role, Hadar plans and orchestrates production activities across the department, ensuring every order to the production team of sources is executed with precision and urgency. She thrives in complexity, drawing energy from the daily diversity of tasks and the feeling that she is a part of a potentially life-changing purpose. “This isn’t just work - it’s a mission,” she says. “You feel like a true partner in something that’s already making a difference.”

Away from the production floor, Hadar enjoys the quiet of Ora village, where she’s lived for 15 years, and stays grounded by cooking, baking, and spending time with friends. Her journey - from technician to leadership - is impressive and inspiring. We’re lucky to have her at the heart of Alpha TAU.